Key result
RFA eliminates refractory VT secondary to cardiac metastatic chondrosarcoma with no recurrence at 8 months.
Why the study?
Does radiofrequency ablation eliminate refractory ventricular tachycardia in a patient with cardiac metastasis of extraskeletal mesenchymal chondrosarcoma?
Case Report (n=1)
No
Does radiofrequency ablation eliminate refractory ventricular tachycardia in a patient with cardiac metastasis of extraskeletal mesenchymal chondrosarcoma?
Radiofrequency ablation can be an effective treatment for refractory ventricular tachycardia secondary to cardiac metastasis of extraskeletal mesenchymal chondrosarcoma.
May support ablation for refractory ventricular tachycardia in rare cardiac metastases; hypothesis-generating from single case report.
Ventricular tachycardia (VT) and premature contraction originating from the right ventricular outflow tract (RVOT) usually appear in healthy individuals. Radiofrequency ablation (RFA) is highly effective at resolving this type of arrhythmia. Refractory VT of RVOT is uncommon and occasionally results from cardiac metastasis of extraskeletal mesenchymal chondrosarcomas (ESMC). ESMC is a rare malignant tumor arising from soft tissues. The current study presents the case of a 25-year-old male with severe VT arising from RVOT due to metastasis of an ESMC that originally occurred in the retroperitoneum. The diagnosis was confirmed following echocardiography and cardiac magnetic resonance. VT was eventually eliminated by RFA, and during the 8-month follow-up period the patient did not complain of any palpitations. Holter monitoring confirmed the absence of recurrence.
No takes yet. Share an insight, caveat, or question.
Shi et al. (2016) conducted a case report in Refractory ventricular tachycardia secondary to cardiac metastatic extraskeletal mesenchymal chondrosarcoma (n=1). Radiofrequency ablation was evaluated on Elimination of ventricular tachycardia. Radiofrequency ablation successfully eliminated refractory ventricular tachycardia secondary to cardiac metastatic extraskeletal mesenchymal chondrosarcoma, with no recurrence during an 8-month follow-up.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: